What lies ahead for the pharmaceutical sector in France?

20 June 2017

Following the recent presidential election and before the Parliamentary elections in France, Marcel Lechanteur, president of Lilly France and Benelux, a unit of Eli Lilly (NYSE: LLY) discussed the main issues for the pharmaceutical sector.

According to a blog posting the website of the European Federation of Pharmaceutical Industries and Associations (00EFPIA), he was asked: The French people have just elected their new President. Could you share your thoughts on the results of this election?

“We have no political comment on the French elections, however, as an industrial actor investing in France, we follow closely the evolution of the French political landscape and the various projects that allow us to continue investing heavily in France. We have the largest manufacturing site worldwide in France, in Fegersheim (Alsace),” Mr Lechanteur noted.

In your opinion, what are the most urgent measures that need to be taken by the new President of the Republic in order to strengthen France's attractiveness in the pharmaceutical sector?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK